| 505 |
0 |
0 |
|g 1.
|t Synthetic Vaccines for Infectious and Autoimmune Diseases /
|r Michael Sela --
|g 2.
|t Host Range Restricted, Non-Replicating Vaccinia Virus Vectors as Vaccine Candidates /
|r Bernard Moss, Miles W. Carroll, Linda S. Wyatt, Jack R. Bennink, Vanessa M. Hirsch, Simoy Goldstein, William R. Elkins, Thomas R. Fuerst, Jeffrey D. Lifson, M. Piatak, Nicholas P. Restifo, Willem Overwijk, Ronald Chamberlain, Steven A. Rosenberg and Gerd Sutter --
|g 3.
|t Hybrid Hepatitis B Virus Core Antigen as a Vaccine Carrier Moiety: II. Expression in Avirulent Salmonella spp. for Mucosal Immunization /
|r F. Schodel, S. Kelly, S. Tinge, S. Hopkins, D. Peterson, D. Milich and R. Curtiss III --
|g 4.
|t Synthetic Recombinant Vaccine Induces Anti-Influenza Long-Term Immunity and Cross-Strain Protection /
|r Ruth Arnon and Raphael Levi --
|g 5.
|t Alphavirus-Based Expression Systems /
|r Charles M. Rice --
|g 6.
|t Alphavirus Hybrid Virion Vaccines /
|r A. Shafferman, S. Lustig, Y. Inbar, M. Halevy, P. Schneider, T. Bino, M. Leitner, H. Grosfeld, B. Velan, F. Schodel and S. Cohen --
|g 7.
|t DNA Vaccines for Bacteria and Viruses /
|r J. B. Ulmer, R. R. Deck, A. Yawman, A. Friedman, C. Dewitt, D. Martinez, D. L. Montgomery, J. J. Donnelly and M. A. Liu --
|g 8.
|t New Vaccines against Bacterial Toxins /
|r Rino Rappuoli, Mariagrazia Pizza, Gill Douce and Gordon Dougan --
|g 9.
|t Parameters for the Rational Design of Genetic Toxoid Vaccines /
|r W. Neal Burnette --
|g 10.
|t Protective Immunity Induced by Bacillus anthracis Toxin Mutant Strains /
|r C. Pezard, J.-C. Sirard and M. Mock --
|g 11.
|t Bacterial Outer Membrane Protein Vaccines: The Meningococcal Example /
|r Jan T. Poolman --
|g 12.
|t Changing Paradigms for an HIV Vaccine /
|r Alan M. Schultz --
|g 13.
|t Complexed HIV Envelope as a Target for an AIDS Vaccine /
|r J. M. Gershoni, G. F. Denisova, D. Raviv, B. Stern and J. Zwickel --
|g 14.
|t HIV-Peplotion Vaccine: A Novel Approach to Vaccination against AIDS by Transepithelial Transport of Viral Peptides and Antigens to Langerhans Cells for Induction of Cytolytic T Cells by HLA Class I and CDI Molecules for Long Term Protection /
|r Yechiel Becker --
|g 15.
|t The Role of Adjuvants and Delivery Systems in Modulation of Immune Response to Vaccines /
|r Rajesh K. Gupta, Paul Griffin, Jr., An-Cheng Chang, Rachel Rivera, Roger Anderson, Bradford Rost, Douglas Cecchini, Mary Nicholson and George R. Siber --
|g 16.
|t Unique Immunomodulating Properties of Dimethyl Dioctadecyl Ammonium Bromide (DDA) in Experimental Viral Vaccines /
|r D. Katz, S. Lehrer, O. Galan, B. Lachmi, S. Cohen, I. Inbar, I. Samina, B. Peleg, D. Heller, H. Yadin, D. Chai, E. Freeman, H. Schupper and P. Fuchs --
|g 17.
|t Challenges in the Development of Combination Vaccines /
|r Ronald W. Ellis --
|g 18.
|t Polysaccharide Conjugate Vaccines for the Prevention of Gram-Positive Bacterial Infections /
|r Robert Naso and Ali Fattom --
|g 19.
|t Production of Influenza Virus in Cell Cultures for Vaccine Preparation /
|r O.-W. Merten, C. Hannoun, J.-C. Manuguerra, F. Ventre and S. Petres --
|g 20.
|t Analysis of Bordetella pertussis Suspensions by ELISA and Flow Cytometry /
|r W. Jiskoot, J. Westdijk, C. H. K. Reubsaet and E. C. Beuvery --
|g 21.
|t Clinical Trials of Shigella Vaccines in Israel /
|r D. Cohen, S. Ashkenazi, M. Green, M. Gdalevich, M. Yavzori, N. Orr, G. Robin, R. Slepon, Y. Lerman, C. Block, I. Ashkenazi, D. Taylor, L. Hale, J. Sadoff, R. Schneerson, J. Robbins, M. Wiener and J. Shemer --
|g 22.
|t Hypothesis: How Licensed Vaccines Confer Protective Immunity /
|r John B. Robbins, Rachel Schneerson and Shousun C. Szu --
|g 23.
|t Therapeutic Vaccines: A Pandoric Prospect /
|r R. E. Spier.
|
